ChemBriefADARx Pharmaceuticals targets $1.74 billion valuation in US IPO
ADARx Pharmaceuticals seeks a $1.74 billion valuation in its U.S. IPO, aiming to raise $371.9 million while AbbVie secures a 4.9% stake through a concurrent private placement ahead of its Nasdaq listi
reuters · 2026-09-21 03:34